Europe has the potential to become a leader in the research and development of new medicines, but geopolitical changes require a rethink of healthcare approaches. Policymakers have a choice: continue in the same vein, caring for an increasing number of people. At the same time, budgets stagnate or even decline, or rethink how healthcare is organized and how budgets are allocated. This means taking a more strategic approach to investments that will improve patient health, strengthen healthcare sustainability, and deliver long-term economic growth and security. Adequate intellectual property protection is key to the sustainability of drug development and investment in the EU. The proposed legislative changes in this area may weaken the innovative pharmaceutical industry and widen the gap in competitiveness and availability of medicines, including in Slovakia. It is essential to thoroughly assess these changes and their impact on the healthcare sector.